New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV

– Two-Year Resistance Analysis from CAPELLA Pivotal Trial Reinforces Sunlenca as a Person-Centered Option in Combination with an Optimized Background Regimen –


– Latest Research Highlights...

Related Keywords

Australia ,United States ,Canada ,Poland ,Warsaw ,L67 ,United Arab Emirates ,Japan ,Foster City ,California ,United Kingdom ,Israel ,Switzerland ,Jared Baeten ,Informationfor Sunlenca ,Gilead Sciences ,Gilead Sciences Inc ,Nasdaq ,Exchange Commission ,European Union ,Clinical Development ,Vice President ,Year Resistance ,Healthcare Professionals ,Study Coordinators ,Important Safety Information ,Safety Information ,Antiretroviral Pregnancy Registry ,Funders Concerned About ,Private Securities Litigation Reform Act ,Quarterly Report ,Prescribing Informationfor Sunlenca ,Markets ,